Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H16ClFN6 |
InChIKeyPPGUULSJUXLSJS-OLZOCXBDSA-N |
CAS Registry2920000-86-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 20 Mar 2023 |





